2026年11月19日,加州大学伯克利分校的研究人员在Justin Y. Lee和Anders Näär的带领下公布了一项关于肥胖治疗新策略的成果,指出一种名为5-tetradecyloxy-2-furoic acid(简称TOFA)的实验性化合物能够通过激活PPARα和PPARδ受体促进脂肪燃烧,并抑制ACC酶以减少脂质合成,从而显著增加身体的能量消耗 1。与现有主要通过抑制食欲来减轻体重的药物不同,该化合物在小鼠实验中展现了通过提高代谢支出而非减少摄入来干预体重控制的能力 1。主要研究者Anders Näär教授解释道:“体重受两个杠杆影响:摄入更少的卡路里,或支出更多的能量……我们瞄准了后者。” 1
在小鼠模型进行的实验中,TOFA使受试对象的能量消耗最高增加了18%,并在有效减少体脂和肝脏脂肪含量的同时保留了肌肉质量 1。研究还显示,当TOFA与semaglutide(如Ozempic/Wegovy)或tirzepatide(如Mounjaro/Zepbound)等GLP-1类药物联合使用时,其减重效果优于单独使用任何一种疗法 1。
相关研究成果已发表在《科学进展》(Science Advances, 2026; 12 (34))上 1。尽管前景广阔,但研究人员强调该化合物目前仅在动物实验中验证有效,其在人类中的安全性和有效性尚未经过测试 1。为了推动后续的临床开发进程,研究团队已成立生物技术公司ReRx Therapeutics 1。
Researchers at the University of California, Berkeley, have identified an experimental compound named 5-tetradecyloxy-2-furoic acid (TOFA) that reduces body fat without compromising muscle integrity. 1 Unlike existing weight-loss medications that primarily suppress appetite, TOFA operates by increasing the body’s energy expenditure through specific genetic and enzymatic mechanisms. 1 The study was published in the journal Science Advances on November 19, 2026. 1
In mouse trials, administration of TOFA resulted in an increase in energy consumption of up to 18%, leading to a reduction in both overall body fat and liver fat while maintaining muscle mass. 1 The compound achieves these effects by inhibiting the enzyme acetyl-CoA carboxylase (ACC), which decreases lipid production, and by activating the PPARα and PPARδ receptors, which promote fat burning. 1 Anders Näär, a professor involved in the research, explained that weight management is influenced by two main levers: reducing calorie intake or increasing energy output, noting that their approach specifically targets the latter. 1
The efficacy of TOFA appears to be enhanced when combined with GLP-1 receptor agonists such as semaglutide (marketed as Ozempic or Wegovy) or tirzepatide (Mounjaro or Zepbound). 1 In combination therapy tests, these pairings yielded better results than either treatment used alone. 1 Although the findings are promising, the safety and effectiveness of TOFA in humans remain unverified as it has only been tested in animal models so far. 1 To facilitate future clinical development, the research team has established a biotechnology company called ReRx Therapeutics. 1
评论
还没有评论,欢迎留下第一条。